Investor Ideas #Potcasts
561, #Cannabis News and #Stocks on the Move; (CSE: $XTRX.C), (CSE: $TER.C),
(NASDAQ: $CRON) (TSX: $CRON.TO), (CSE: $TRIP.C) (NASDAQ: $MNMD)
Delta, Kelowna, BC, May 7, 2021 (Investorideas.com Newswire)
www.Investorideas.com, a global news source covering leading sectors including
marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/050721-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2021/cannabis-potcasts/05071XTRX-TER-CRON-TRIP-MNMD.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
Today’s
podcast is sponsored by Phyto
Extractions Inc. (CSE:XTRX), an agricultural-scale cannabis
extraction, distillation and product manufacturer located in Langley, BC at its
co-located Health Canada Licensed Standard Processing (extraction, no
cultivation), Sales (extracts, topicals, and edibles) through Adastra Labs Inc.
and Analytical Testing Laboratory through Chemia Analytics Inc. Adastra Labs
also has a pending Health Canada R&D license amendment.
In
today’s podcast we look at a few public company announcements.
TerrAscend
Corp.
(CSE:TER) (OTCQX: TRSSF), a leading North American
cannabis operator, today announced the grand opening of its
second New Jersey medical cannabis dispensary.
The 6,500 square foot dispensary,
located at 1865 Springfield Avenue in Maplewood, features interactive product
displays and a large "bud bar'' where customers can see and smell flower
products before purchasing. Patients can access a wide selection of
TerrAscend's Kind Tree flower, vapes and syringes, as well as an assortment of
other brands. A designated express pickup area for online orders and digital menus
in the lobby make for quick and easy shopping.
TerrAscend is vertically integrated
in New Jersey with one of the state's largest cultivation and manufacturing
facilities.
"To say that we're excited
about the opening of The Apothecarium Maplewood, would be an
understatement," said Jason Wild, Executive Chairman of TerrAscend.
"The size, aesthetic and throughput capacity of our new dispensary
combined with the availability of high-quality Kind Tree flower, vapes and
syringes from our recently completed indoor facility, sets The Apothecarium
Maplewood up to be one of the top performing dispensaries in the U.S."
Greg Rochlin, CEO of TerrAscend
Northeast, added, "Providing our high-quality products and service to
patients and caregivers is core to TerrAscend's mission. I believe this
dispensary sets the bar for quality in the state and I'd like to thank our team
for their hard work in creating this beautiful space." Mr. Rochlin
continued, "I would also like to thank the newly seated New Jersey
Cannabis Regulatory Commission for allowing The Apothecarium Maplewood to be
the first Commission approved dispensary in the state."
Red
Light Holland Corp. (CSE: TRIP), an Ontario-based corporation
engaged in the production, growth and sale of a premium brand of magic truffles
to the legal, recreational market within the Netherlands, recently provided an update on its
intellectual property as the Company has received patent pending status for the
customization and personalization of microdosing kits and protocols based on
biometric and movement data, for the Company's natural occurring consumer goods
product consisting of raw, natural and unprocessed magic truffles.
"Biometric data, especially our
pose and the way we move, is an untapped gold mine of data that can help us
understand what is happening in our subconscious. Utilizing this data to help
people find the psilocybin microdose that works best for them can potentially
be a breakthrough in personalization of wellness applications," said Sarah
Hashkes, Red Light Holland's Chief Technology and Innovation Officer. "This
innovation brings together two of the most promising tools we have to promote
growth, embodiment practices and psychedelics and is part of the larger scope
of scientifically based support structures Red Light Holland is creating to
ensure the increase in neural plasticity caused by psychedelics is accompanied
with a 'set and setting' that help people make the most out of naturally
occurring psilocybin."
"Working with natural
substances and combining them with cutting edge innovation and proprietary
technology to hopefully help people as opposed to limiting people, is now the
way of the future," added Todd Shapiro, CEO and Director of Red Light
Holland. "Red Light Holland's progressiveness, creativity and pure belief
in providing access, coupled with Sarah Hashkes' expertise, and the help of our
Senior Advisor, IP lawyer and psychedelics advocate, Graham Pechenik, generates
the precise combination of experience, forethought and understanding of natural
occurring psilocybin to potentially prove out the benefits of and change the
stigma around the use of these magical substances. Learning about these
potential benefits and being a part of developing precise dosages for the
betterment of consumers is now a more realistic goal for Red Light
Holland."
Red Light Holland's newest
innovation also incorporates the ground-breaking advancements in its iMicro
Digital Care App and its Wisdom Truffle, further contributing to a growing
technology ecosystem designed to allow consumers to obtain the greatest
possible benefit from their microdosing journeys.
Evidence for the benefits of
psilocybin continues to accumulate, and people who microdose
psilocybin-containing mushrooms report improvements in mood, focus, creativity,
and general well-being, as well as the amelioration of symptoms of mental
health issues. (See, e.g., Anderson et
al., Microdosing psychedelics: personality, mental health, and creativity
differences in microdosers. Psychopharmacol. (Berl). 236, 731-740 (2019); Lea
et al., Psychedelic Microdosing: A Subreddit Analysis. J. Psychoactive Drugs
52, 101-112 (2020).)
Meanwhile, acceptance of psilocybin
continues to spread, with voters in Oregon legalizing the use of psilocybin and
psilocybin-containing fungi for therapy, and numerous other jurisdictions
moving toward legalization or decriminalization. Despite this growing body of
evidence, and despite the increasing acceptance of its use both as a medicine
and for the betterment of healthy people, little is currently known about how
dosage amounts and protocols can be optimized for specific individuals. This is
particularly true in the case of microdosing, and those interested in achieving
the benefits of microdosing must generally rely on trial and error, or
expensive coaches, and there is no assurance that either will lead to optimal
outcomes. Working to overcome these hurdles, ongoing research by inventor Sarah
Hashkes, CTIO of Red Light Holland, has resulted in a novel approach to
microdosing, which enables personalized dosing amounts and protocols that are
based on collected biometric and movement data, and correlated with the
qualities and characteristics of Red Light Holland's natural products.
Mind
Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), a leading psychedelic-inspired
medicine company announced the launch of its Project Angie to
advance the development of psychedelics, including LSD, to treat pain
conditions. MindMed is currently exploring two primary clinical indications for
the treatment of pain.
For the commencement of Project
Angie, MindMed will initiate a study of LSD in a severe pain indication.
MindMed is currently preparing a pre-IND briefing package for this Phase 2a
Proof of Concept study which it plans to submit to the FDA in the second half
of 2021. In addition, the Company is also evaluating a second indication in a
common, often debilitating, chronic pain syndrome.
Patients experiencing chronic pain
represent a large and growing segment of the population and, according to
IQVIA, the global market for analgesics is expected to grow over $31 billion by
2030. At the same time, overuse of opioids in the treatment of pain has
contributed to the opioid epidemic in the United States and around the world.
There has been little innovation in the pain market in decades and the
treatment paradigm is still dominated by opioids and nonsteroidal
anti-inflammatory drugs (NSAIDs).
Preliminary evidence, including a
clinical study co-authored by MindMed collaborating researchers Prof. Dr.
Matthias Liechti and Dr. Kim Kuypers, suggests that psychedelics may offer an
entirely novel mechanism of action for treating pain, which could ultimately
offer patients a new treatment option. The exact mechanisms by which
psychedelics may carry out their analgesic effect have not been fully
characterized but may involve direct effects on endogenous pain modulation
pathways. This mechanism is particularly relevant as altered function, or
dysfunction, of these pain modulation pathways has been implicated in a range
of pain syndromes.
"Evidence dating back to the
1950s suggests that LSD and other psychedelics may have analgesic effects, but
this treatment area remains largely untapped by companies studying
psychedelics, with the majority of research focusing solely on psychiatric
indications" said MindMed Chief Development Officer, Rob Barrow.
MindMed CEO & Co-Founder J.R.
Rahn said "With the launch of Project Angie, we seek to align closely with
MindMed's core mission to improve mental health and combat substance use for
the many patients in need. If we can help to develop a new paradigm to treat
pain, it may have the potential to greatly reduce the use of addictive
medicines such as opioids currently ravaging society and its mental
health."
Cronos
Group Inc. (NASDAQ: CRON) (TSX: CRON), today announced its 2021 First Quarter
business results.
“This quarter for Cronos Group would
not have been possible without the tenacious and innovative efforts put forward
by every Cronos employee across our organization. In the first quarter of 2021
our results in Canada were impacted by market dynamics due to the COVID-19
pandemic and ensuing stay-at-home orders and various other restrictions.
Despite this, we continued to push forward our innovation pipeline and execute
on our strategy, which was a true testament to the strength of our team,” said
Kurt Schmidt, President and CEO, Cronos Group.
“In March, we were recognized as one
of Fast Company’s Most Innovative Companies for our joint venture with Ginkgo
Bioworks to produce cannabinoids using biosynthesis. Our partnership with
Ginkgo is critical to executing our Company’s vision: to transform industries
through cannabinoid innovation. A critical component to commercializing
fermented cannabinoids is a Health Canada processing license, which Cronos
Fermentation received in April. Receiving this license is a great
accomplishment and I am looking forward to bringing our innovative product
pipeline to market over time utilizing this technology. This partnership is a
global effort for our organization, and it is a great demonstration of how our
research and development and innovation teams across regions work together to
push critical projects forward. Last month, we also announced our U.S. Cronos
Employees Political Action Committee as well as a robust Marketing Code of
Conduct that all of our brands and employees have pledged to uphold. We’re
proud to be on the record supporting responsible legalization efforts in the
United States.”
Financial Results
|
(in
thousands of U.S. dollars) |
|
Three
months ended March 31, |
|
Change |
|||||||||||||||
|
|
|
2021 |
|
2020 |
|
$ |
|
% |
|||||||||||
|
Net
revenue |
|
|
|
|
|
|
|
|
|||||||||||
|
United
States |
|
$ |
2,441 |
|
|
|
$ |
2,176 |
|
|
|
$ |
265 |
|
|
|
12 |
|
% |
|
Rest
of World |
|
10,170 |
|
|
|
6,256 |
|
|
|
3,914 |
|
|
|
63 |
|
% |
|||
|
Consolidated
net revenue |
|
12,611 |
|
|
|
8,432 |
|
|
|
4,179 |
|
|
|
50 |
|
% |
|||
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Gross
profit (loss) |
|
$ |
(2,963 |
) |
|
|
$ |
(6,476 |
) |
|
|
$ |
3,513 |
|
|
|
(54 |
) |
% |
|
Gross
margin |
|
(23 |
) |
% |
|
(77 |
) |
% |
|
N/A |
|
54 |
|
pp |
|||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Adjusted
EBITDA (i) |
|
$ |
(37,075 |
) |
|
|
$ |
(37,055 |
) |
|
|
$ |
(20 |
) |
|
|
— |
|
% |
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Other
Data |
|
|
|
|
|
|
|
|
|||||||||||
|
Cash
and cash equivalents (ii) |
|
$ |
1,024,450 |
|
|
|
$ |
1,128,396 |
|
|
|
$ |
(103,946 |
) |
|
|
(9 |
) |
% |
|
Short-term
investments (ii) |
|
214,925 |
|
|
|
206,230 |
|
|
|
8,695 |
|
|
|
4 |
|
% |
|||
|
Capital
expenditures |
|
7,072 |
|
|
|
7,516 |
|
|
|
(444 |
) |
|
|
(6 |
) |
% |
|||
(i) See “Non-GAAP
Measures” for more information, including a reconciliation of adjusted earnings
(loss) before interest, taxes, depreciation and amortization (“Adjusted
EBITDA”)
(ii) Dollar amounts
are as of the last day of the period indicated
First
Quarter 2021
●
Net revenue of $12.6 million in Q1 2021
increased by $4.2 million from Q1 2020. The increase year-over-year was
primarily driven by continued growth in the adult-use Canadian cannabis market,
sales in the Israeli medical cannabis market, and an increase in sales in the
U.S. segment driven by new U.S. hemp-derived CBD products introductions,
partially offset by strategic price reductions on various adult-use cannabis products
in Canada in the second half of 2020.
●
Gross loss of $3.0 million in Q1 2021
decreased by $3.5 million from Q1 2020. The decrease in losses year-over-year
was primarily driven by an increase in net revenue and a decrease in inventory
write-downs in the Rest of World ("ROW") segment.
●
Adjusted EBITDA loss of $37.1 million in Q1
2021 increased marginally from Q1 2020. The marginal increase in losses
year-over-year was primarily driven by an increase in sales and marketing costs
due to brand development in the U.S. segment, and an increase in research and
development ("R&D") costs driven by increased spending on product
development and developing cannabinoid intellectual property. Partially offset
by decreases in sales and marketing spend in the ROW segment, gross loss and
general and administrative expenses.
Once again, today’s podcast is sponsored by Phyto Extractions Inc. (CSE:XTRX), an agricultural-scale cannabis extraction, distillation and product manufacturer located in Langley, BC at its co-located Health Canada Licensed Standard Processing (extraction, no cultivation), Sales (extracts, topicals, and edibles) through Adastra Labs Inc. and Analytical Testing Laboratory through Chemia Analytics Inc. Adastra Labs also has a pending Health Canada R&D license amendment.
Investor
ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and that this podcast is not an endorsement to buy
products or services or securities. Investors are reminded all investment
involves risk and possible loss of investment.
Learn
more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To
hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The
Investorideas.com podcasts are also available on iTunes ( Apple Podcasts)
, Audible , Spotify, Tunein, Stitcher,
Spreaker.com, iHeartRadio , Google Play
Music and most audio platforms available.
Potcasts
is now a certified word mark Trademark on the blockchain through Cognate, Inc.
CM Certification-Registration Number: 10468217708
About
Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts
and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech,
water, renewable energy and more. Investor Idea’s original branded content
includes the following podcasts and columns : Crypto
Corner , Play by Play sports and stock news column, Investor
Ideas Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
